-

12:28:13 AM

NVCN Stock News

NVCN - Neovasc Inc

04/11/23 8:20 AM

Nasdaq : NVCN

acquisition

Shockwave Medical Completes Acquisition of Neovasc

via NewMediaWire – Shockwave Medical, Inc. (NASDAQ: SWAV) (“Shockwave”), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, today announced the completion of its previously

RHEA-AI

neutral

03/31/23 4:11 PM

Nasdaq : NVCN

earnings

Neovasc Announces Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Corporate Update

via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today reported financial results for the fourth quarter and year ended December 31, 2022. Recent Highlights · Generated revenue of $1.45 million

RHEA-AI

negative

03/06/23 5:37 PM

Nasdaq : NVCN

acquisition

Neovasc Shareholders Approve Acquisition by Shockwave Medical

via NewMediaWire – Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive devices for the treatment of refractory angina, is pleased to announce that its Shareholders (as defined

RHEA-AI

neutral

02/01/23 9:05 AM

Nasdaq : NVCN

Neovasc Announces German Reimbursement Renewal

via NewMediaWire – Neovasc, Inc. (“Neovasc” or “the Company”) ( NASDAQ, TSX : NVCN) today announced the German Institute for the Hospital Remuneration System (“InEK”) has awarded the Neovasc Reducer™ (“Reducer”), a CE-Marked medical

RHEA-AI

very positive

01/17/23 8:00 AM

Nasdaq : NVCN

acquisition

Shockwave Medical to Acquire Neovasc

Neovasc Inc. (" Neovasc" or the " Company") (NASDAQ,TSX: NVCN), a leader in the development of minimally invasive devices for the treatment of refractory angina, announced today that the Company has entered into a binding

RHEA-AI

very positive

11/28/22 4:45 PM

Nasdaq : NVCN

clinical trial

Neovasc Announces Progress on COSIRA-II Clinical Trial

via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) ( NASDAQ, TSX : NVCN) today announced an update on the COSIRA-II Clinical Trial (“Trial”) status. COSIRA-II is the U.S. Investigational Device Exemption (“IDE”) pivotal

RHEA-AI

very positive

11/18/22 9:05 AM

Nasdaq : NVCN

Neovasc Comments on European Heart Journal Publication

via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) ( NASDAQ, TSX : NVCN) today announced that European Heart Journal - Case Reports has published an article titled, “Implantation of the Coronary Sinus Reducer for Refractory

RHEA-AI

neutral

11/10/22 4:05 PM

Nasdaq : NVCN

earnings

Neovasc Announces Third Quarter Financial Results and Provides Corporate Update

via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today reported financial results for the third quarter ended September 30, 2022. Recent Highlights Generated revenues of $923,000, a quarterly record and a

RHEA-AI

neutral

11/08/22 9:05 AM

Nasdaq : NVCN

Neovasc Reducer Obtains U.S. Outpatient Reimbursement

Neovasc Inc. (“Neovasc” or the “Company”) ( NASDAQ , TSX : NVCN) today announced that the Centers for Medicare and Medicaid Services (“CMS”) has assigned the Neovasc Reducer™ (“Reducer”) implant procedure a new

RHEA-AI

very positive

10/27/22 9:00 AM

Nasdaq : NVCN

conferencesearnings

Neovasc to Report Third Quarter Financial Results on November 10, 2022

Neovasc Inc. ( NASDAQ , TSX : NVCN) will report financial results for the quarter ended September 30, 2022 on Thursday, November 10, 2022. Neovasc’s President and Chief Executive Officer Fred Colen, and Chris Clark,

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next

NVCN Data

IndustrySurgical and Medical Instrument Manufacturing
Websitewww.neovasc.com
CeoFred Colen
Security nameNeovasc Inc
Issue typecs
SectorManufacturing
Sic code3841
Employees54
Tags
- Health Technology
- Medical Specialties
- Manufacturing
- Surgical and Medical Instrument Manufacturing
AddressRichmond
Address25138-13562 Maycrest Way
StateBritish Columbia
CityRichmond
ZipV6V 2J7
CountryCanada
Phone16042704344

About Neovasc Inc

Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include Reducer, for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and Tiara, for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada, Israel and Europe.